HomeHealthJapan's Gunma prefecture reports contaminant in Moderna COVID-19 vaccine

Japan’s Gunma prefecture reports contaminant in Moderna COVID-19 vaccine

- Advertisement -spot_img

Medical staff prepares Moderna coronavirus disease (COVID-19) vaccine to be administered at the newly-opened mass vaccination centre in Tokyo, Japan, May 24, 2021. Carl Court/Pool via REUTERS/File Photo/File Photo

TOKYO, Aug 30 (Reuters) – A contaminant was found in Moderna’s COVID-19 vaccine on Sunday in Japan’s Gunma prefecture, near Tokyo, the latest such case in the country involving the U.S. company’s vaccines.

A tiny, black substance was found in a Moderna Inc (MRNA.O) vaccine vial, prompting the prefecture to suspend inoculation using vaccines from the Moderna lot from which the vial had come, a Gunma prefecture official said.

Japan’s health ministry said on Saturday two people died after receiving Moderna’s vaccine shots that were among lots later suspended following the discovery of contaminants.

The government had said that no safety or efficacy issues had been identified and that the suspension was a precaution. The causes of death are being investigated. read more

Last week, Japan halted the use of 1.63 million Moderna doses, shipped to 863 vaccination centres nationwide, after the domestic distributor, Takeda Pharmaceutical (4502.T), received reports of contaminants in some vials.

Moderna and Spanish pharma company Rovi (ROVI.MC), which bottles Moderna vaccines for markets other than the United States, had said at the time that the contamination could be due to a manufacturing issue in one of Rovi’s production lines.

The vaccine in question in Gunma is from a Moderna lot that is different from those whose use has already been suspended, the Gunma official said.

Vaccines from the same lot have been administered to 4,575 people in Gunma, but the prefecture has heard no reports of ill health, the official said.

Contaminants were found in Moderna vaccines in Japan’s southern prefecture of Okinawa, as well. read more

Reporting by Kiyoshi Takenaka; Editing by Himani Sarkar

Our Standards: The Thomson Reuters Trust Principles.


- Advertisement -spot_img
- Advertisement -spot_img
Stay Connected
Must Read
- Advertisement -spot_img
Related News
- Advertisement -spot_img